Can I read Mammalian Target of Rapamycin Inhibition as Therapy for Hematologic Malignancies on EtoBox?

Mammalian Target of Rapamycin Inhibition as Therapy for Hematologic Malignancies by Amit Panwalkar; Srdan Verstovsek; Francis J. Giles is a Medicine article available to read on EtoBox.

What is Mammalian Target of Rapamycin Inhibition as Therapy for Hematologic Malignancies about?

## Abstract The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3‐kinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signal‐transduction pathways, is involved in the coupling of growth stimuli with cell cycle progression, and initiates mRNA translation in response to favorable nutrient environments. mTOR is involved in regulating many aspects of cell growth, including membrane traffic, protein degradation, protein kinase C signaling, ribosome biogenesis, and transcription. Because mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4E‐binding protein 1, its inhibitors cause G~1~‐phase cell cycle arrest. Inhibitors of mTOR also prevent cyclin dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which may help cause G~1~‐phase arrest. It is known that the phosphatase and tensin homologue tumor suppressor gene (PTEN) plays a major role in embryonic development, cell migration, and

Who reads Mammalian Target of Rapamycin Inhibition as Therapy for Hematologic Malignancies?

Author

Amit Panwalkar; Srdan Verstovsek; Francis J. Giles

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0008-543X)

Published

2004

Language

EN

Field

Medicine (Health Sciences)